{"id":"kaletra-tablets","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":"20-30","effect":"Elevated cholesterol/triglycerides"},{"rate":"2-5","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir is an HIV protease inhibitor that blocks the viral protease enzyme required for HIV maturation and infectivity. Ritonavir is a potent protease inhibitor used at sub-therapeutic doses as a pharmacokinetic booster to inhibit cytochrome P450 metabolism, thereby increasing lopinavir plasma concentrations and half-life. Together, they suppress HIV replication and reduce viral load in infected patients.","oneSentence":"Kaletra is a combination of lopinavir and ritonavir that inhibits HIV protease to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:06.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"COVID-19 (investigational use in phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05914116","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2023-08-17","conditions":"Advanced Solid Tumors","enrollment":862},{"nctId":"NCT07002242","phase":"PHASE1","title":"A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Aluvia","status":"COMPLETED","sponsor":"Henan Genuine Biotech Co., Ltd.","startDate":"2022-07-06","conditions":"Healthy","enrollment":15},{"nctId":"NCT01513122","phase":"PHASE4","title":"Bone and Body Comp: A Sub Study of the SECOND-LINE Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2010-02","conditions":"HIV","enrollment":210},{"nctId":"NCT04487145","phase":"PHASE4","title":"Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-11-23","conditions":"Drug-Drug Interaction, HIV Infection","enrollment":194},{"nctId":"NCT04466241","phase":"PHASE2, PHASE3","title":"Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-11-27","conditions":"COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":294},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT04372628","phase":"PHASE2","title":"Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2020-06-01","conditions":"COVID-19","enrollment":452},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT02227238","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-11","conditions":"HIV Infections","enrollment":627},{"nctId":"NCT04328285","phase":"PHASE3","title":"Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2020-04-14","conditions":"COVID-19","enrollment":118},{"nctId":"NCT04425382","phase":"","title":"Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2020-03-01","conditions":"Coronavirus, COVID, Pneumonia","enrollment":400},{"nctId":"NCT05302947","phase":"","title":"COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2020-02-01","conditions":"COVID-19, Mild to Moderate","enrollment":154},{"nctId":"NCT04261907","phase":"NA","title":"Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection","status":"TERMINATED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-02-11","conditions":"2019-nCoV","enrollment":6},{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT04360980","phase":"PHASE2","title":"The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-03-20","conditions":"COVID-19","enrollment":80},{"nctId":"NCT00344487","phase":"NA","title":"Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2005-12","conditions":"HIV","enrollment":3},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT01571414","phase":"PHASE1","title":"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05","conditions":"Tuberculosis","enrollment":52},{"nctId":"NCT01172535","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"HIV","enrollment":97},{"nctId":"NCT00084149","phase":"PHASE2","title":"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00270296","phase":"PHASE2","title":"Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT04365582","phase":"PHASE3","title":"OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome","status":"WITHDRAWN","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2020-05-07","conditions":"COVID","enrollment":""},{"nctId":"NCT04403100","phase":"PHASE3","title":"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: \"The Hope Coalition - 1\"","status":"UNKNOWN","sponsor":"Cardresearch","startDate":"2020-06-03","conditions":"COVID-19, Coronavirus Infection, Virus Disease","enrollment":1968},{"nctId":"NCT04386876","phase":"PHASE1","title":"Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions","status":"COMPLETED","sponsor":"World Medicine ILAC SAN. ve TIC. A.S.","startDate":"2020-04-30","conditions":"Bioequivalence","enrollment":30},{"nctId":"NCT04403646","phase":"NA","title":"Tannin Specific Natural Extract for COVID-19 Infection","status":"TERMINATED","sponsor":"Hospital de Clinicas José de San Martín","startDate":"2020-06-12","conditions":"COVID-19, SARS-CoV 2, Coronavirus Infection","enrollment":124},{"nctId":"NCT00679926","phase":"PHASE4","title":"Kaletra and Viread in Antiretroviral Naïve Patients","status":"TERMINATED","sponsor":"Oklahoma State University Center for Health Sciences","startDate":"2008-05","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT04645433","phase":"","title":"Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit","status":"COMPLETED","sponsor":"Sisli Hamidiye Etfal Training and Research Hospital","startDate":"2020-03-15","conditions":"Mortality, Intensive Care Unit","enrollment":100},{"nctId":"NCT00665951","phase":"PHASE1","title":"Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-09","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT04542694","phase":"PHASE3","title":"Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-05-21","conditions":"COVID-19","enrollment":200},{"nctId":"NCT01068873","phase":"PHASE4","title":"Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)","status":"TERMINATED","sponsor":"Temple University","startDate":"2010-04","conditions":"HIV Infections","enrollment":1},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00621166","phase":"PHASE2","title":"Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-06","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00802334","phase":"PHASE2","title":"TDM of Generic Lopinavir/Ritonavir 200/50 mg","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-01","conditions":"HIV","enrollment":70},{"nctId":"NCT01159275","phase":"PHASE1, PHASE2","title":"Lopinavir (LPV) Dose Reduction","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2009-07","conditions":"HIV-1 Infections","enrollment":20},{"nctId":"NCT04252885","phase":"PHASE4","title":"The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection","status":"COMPLETED","sponsor":"Guangzhou 8th People's Hospital","startDate":"2020-01-28","conditions":"Coronavirus Infections","enrollment":86},{"nctId":"NCT04434248","phase":"PHASE2, PHASE3","title":"An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Chromis LLC","startDate":"2020-04-23","conditions":"COVID-19","enrollment":330},{"nctId":"NCT04376814","phase":"NA","title":"Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19","status":"COMPLETED","sponsor":"Baqiyatallah Medical Sciences University","startDate":"2020-03-29","conditions":"COVID-19, Favipiravir, Kaletra","enrollment":40},{"nctId":"NCT04307693","phase":"PHASE2","title":"Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2020-03-11","conditions":"COVID-19","enrollment":65},{"nctId":"NCT04275388","phase":"","title":"Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia","status":"UNKNOWN","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2020-05-15","conditions":"2019 Novel Coronavirus Pneumonia","enrollment":426},{"nctId":"NCT04388514","phase":"NA","title":"Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2020-04-08","conditions":"SARS-CoV-2 Respiratory Failure","enrollment":90},{"nctId":"NCT04358614","phase":"PHASE2, PHASE3","title":"Baricitinib Therapy in COVID-19","status":"COMPLETED","sponsor":"Fabrizio Cantini","startDate":"2020-03-16","conditions":"COVID, Pneumonia","enrollment":12},{"nctId":"NCT04320277","phase":"PHASE2, PHASE3","title":"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","status":"UNKNOWN","sponsor":"Hospital of Prato","startDate":"2020-05-16","conditions":"Pharmacological Action","enrollment":200},{"nctId":"NCT04323345","phase":"PHASE3","title":"Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","status":"UNKNOWN","sponsor":"Misr University for Science and Technology","startDate":"2020-04-15","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04331470","phase":"PHASE2, PHASE3","title":"Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19","status":"UNKNOWN","sponsor":"Fasa University of Medical Sciences","startDate":"2020-04-04","conditions":"COVID-19","enrollment":30},{"nctId":"NCT04295551","phase":"NA","title":"Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","status":"UNKNOWN","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2020-03-14","conditions":"COVID-19","enrollment":80},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT04286503","phase":"PHASE4","title":"The Clinical Study of Carrimycin on Treatment Patients With COVID-19","status":"UNKNOWN","sponsor":"Beijing YouAn Hospital","startDate":"2020-02-23","conditions":"Novel Coronavirus Infectious Disease (COVID-19)","enrollment":520},{"nctId":"NCT02415985","phase":"PHASE2","title":"Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2015-06","conditions":"HIV, Tuberculosis","enrollment":40},{"nctId":"NCT00661349","phase":"PHASE4","title":"Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients","status":"TERMINATED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-02","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT03836833","phase":"PHASE1, PHASE2","title":"Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2019-06-04","conditions":"HIV","enrollment":50},{"nctId":"NCT02581202","phase":"","title":"The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-21","conditions":"HIV-1 Infection","enrollment":216},{"nctId":"NCT01700790","phase":"PHASE4","title":"Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin","status":"TERMINATED","sponsor":"University of Miami","startDate":"2016-02","conditions":"AIDS, Tuberculosis","enrollment":9},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00608569","phase":"NA","title":"Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV Infections","enrollment":529},{"nctId":"NCT00632970","phase":"PHASE4","title":"Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals","status":"TERMINATED","sponsor":"George Washington University","startDate":"2008-02","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT00949234","phase":"PHASE2","title":"Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-03","conditions":"HIV Prevention, HIV Infections","enrollment":267},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT01097655","phase":"","title":"Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2006-08","conditions":"Human Immunodeficiency Virus","enrollment":3049},{"nctId":"NCT01003990","phase":"PHASE3","title":"Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-10","conditions":"HIV","enrollment":710},{"nctId":"NCT01045369","phase":"PHASE4","title":"A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects","status":"COMPLETED","sponsor":"Therapeutic Concepts","startDate":"2010-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01146873","phase":"PHASE3","title":"Treatment Options for Protease Inhibitor-exposed Children","status":"COMPLETED","sponsor":"Columbia University","startDate":"2010-07","conditions":"HIV/AIDS, HIV Infections","enrollment":300},{"nctId":"NCT00928187","phase":"PHASE3","title":"Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-11","conditions":"HIV, HIV Infections","enrollment":454},{"nctId":"NCT02198443","phase":"PHASE4","title":"Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2015-06-06","conditions":"HIV","enrollment":160},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT01083173","phase":"","title":"Surveillance of Kaletra in Korean Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-10","conditions":"HIV-1 Infection","enrollment":595},{"nctId":"NCT00409591","phase":"PHASE3","title":"Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand","status":"TERMINATED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2008-07","conditions":"HIV Infections, Pregnancy","enrollment":435},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT02159352","phase":"PHASE1","title":"Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C","enrollment":49},{"nctId":"NCT00654147","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects","status":"COMPLETED","sponsor":"Margaret A. Fischl, M.D.","startDate":"2008-04","conditions":"HIV Infections","enrollment":44},{"nctId":"NCT01088516","phase":"PHASE4","title":"Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa","status":"COMPLETED","sponsor":"University of Zambia","startDate":"2008-12","conditions":"HIV","enrollment":280},{"nctId":"NCT00771498","phase":"PHASE4","title":"An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2008-11","conditions":"HIV Infection, Tuberculosis","enrollment":30},{"nctId":"NCT01139905","phase":"PHASE2","title":"Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-04","conditions":"HIV-1 Infections","enrollment":24},{"nctId":"NCT01307124","phase":"PHASE3","title":"Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-03","conditions":"HIV-infected Children","enrollment":199},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01328158","phase":"","title":"Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06","conditions":"Human Immunodeficiency Virus Infection","enrollment":236},{"nctId":"NCT01737359","phase":"PHASE2","title":"A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.","status":"TERMINATED","sponsor":"RFS Pharma, LLC","startDate":"2012-12","conditions":"Human Immunodeficiency Virus Infection","enrollment":2},{"nctId":"NCT00834457","phase":"PHASE2, PHASE3","title":"A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe","status":"COMPLETED","sponsor":"Parirenyatwa Hospital","startDate":"2007-06","conditions":"AIDS-related Kaposi's Sarcoma","enrollment":49},{"nctId":"NCT00100646","phase":"NA","title":"Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2007-03","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00946595","phase":"PHASE2, PHASE3","title":"Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-11","conditions":"HIV Infections","enrollment":420},{"nctId":"NCT00762320","phase":"NA","title":"Comparison of Liquid Kaletra and Low Dose Kaletra Tablets","status":"COMPLETED","sponsor":"Phoenix Children's Hospital","startDate":"2008-10","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT01196195","phase":"PHASE2, PHASE3","title":"KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2010-08","conditions":"Antiretroviral Therapy in HIV-1 Infected Children","enrollment":173},{"nctId":"NCT00605098","phase":"PHASE4","title":"Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2008-02","conditions":"HIV Infections, Pregnancy","enrollment":60},{"nctId":"NCT00697892","phase":"PHASE1","title":"Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations","status":"COMPLETED","sponsor":"Fran Aweeka","startDate":"2005-07","conditions":"HIV Infections, Malaria","enrollment":38},{"nctId":"NCT01383005","phase":"","title":"Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06","conditions":"Human Immunodeficiency Virus Infection","enrollment":97},{"nctId":"NCT01031849","phase":"PHASE4","title":"Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir","status":"TERMINATED","sponsor":"Ines Perez","startDate":"2010-02","conditions":"HIV Infections","enrollment":7},{"nctId":"NCT01166477","phase":"PHASE4","title":"Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor","status":"COMPLETED","sponsor":"Sociedad Andaluza de Enfermedades Infecciosas","startDate":"2010-01","conditions":"HIV Infection","enrollment":228},{"nctId":"NCT00414518","phase":"NA","title":"Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-01","conditions":"HIV Infections","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Kaletra Tablets","genericName":"Kaletra Tablets","companyName":"Ottawa Hospital Research Institute","companyId":"ottawa-hospital-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Kaletra is a combination of lopinavir and ritonavir that inhibits HIV protease to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3 trials).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}